Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 118 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 A Message from the ESMO President March 17, 2020 Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans July 31, 2019 Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... April 30, 2024 Load more HOT NEWS Study Says Exercise Combats Side Effects of Chemo and Other Meds... New on NCI’s Websites for September 2020 Self-care Isn’t Selfish Opinion: ‘We need to increase testing in primary care’
